Markus Schwerzmann

Markus Schwerzmann

Auto-generated profile, based on publicly available information

Markus Schwerzmann

Center for Congenital Heart Disease, University Hospital Inselspital, University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
GWGary Webb
Gary Webb
BMBarbara J. Mulder
Barbara J. Mulder
JAJamil Aboulhosn
Jamil Aboulhosn
CDCurt J. Daniels
Curt J. Daniels
MEMaria Amalia Elizari
Maria Amalia Elizari
PKPaul Khairy
Paul Khairy

1 November 2014 in International Journal of Cardiology
Verified
Journal Article
Closed access
TRTitia P.E. Ruys
Titia P.E. Ruys
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
MJMark R. Johnson
Mark R. Johnson
KSKaren Sliwa
Karen Sliwa
LTLuigi Tavazzi
Luigi Tavazzi
JRJolien W. Roos-Hesselink
Jolien W. Roos-Hesselink

29 August 2020 in European Heart Journal
Verified
Journal Article
Closed access
MSMarkus Schwerzmann
Markus Schwerzmann
EGEva Goossens
Eva Goossens
PGPastora Gallego
Pastora Gallego
AKAdrienne H Kovacs
Adrienne H Kovacs
PMPhilip Moons
Philip Moons
CTCorina Thomet
Corina Thomet
Survival prospects in adults with congenital heart disease (CHD), although improved in recent decades, still remain below expectations for the general population. Patients and their loved ones benefit from preparation for both unexpected and predictable deaths, sometimes preceded by a prolonged period of declining health. Hence, advance care planning (ACP) is an integral part of comprehensive care for adults with CHD. This position paper summarizes evidence regarding benefits of and patients’ preferences for ACP and provides practical advice regarding the implementation of ACP processes within clinical adult CHD practice. We suggest that ACP be delivered as a structured process across different stages, with content dependent upon the anticipated disease progression. We acknowledge potential barriers to initiate ACP discussions and emphasize the importance of a sensitive and situation-specific communication style. Conclusions presented in this article reflect agreed expert opinions and include both patient and provider perspectives.

12 December 2020 in European Heart Journal
Verified
Journal Article
Closed access
GDGerhard-Paul Diller
Gerhard-Paul Diller
MGMichael A Gatzoulis
Michael A Gatzoulis
CBCraig S Broberg
Craig S Broberg
JAJamil Aboulhosn
Jamil Aboulhosn
MBMargarita Brida
Margarita Brida
JRJolien W. Roos-Hesselink
Jolien W. Roos-Hesselink
We are witnessing an unparalleled pandemic caused by the novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) associated with coronavirus disease 2019 (COVID-19). Current data show that SARS-CoV-2 results in mild flu-like symptoms in the majority of healthy and young patients affected. Nevertheless, the severity of COVID-19 respiratory syndrome and the risk of adverse or catastrophic outcomes are increased in patients with pre-existing cardiovascular disease. Patients with adult congenital heart disease (ACHD)—by definition—have underlying cardiovascular disease. Many patients with ACHD are also afflicted with residual haemodynamic lesions such as valve dysfunction, diminished ventricular function, arrhythmias or cyanosis, have extracardiac comorbidities, and face additional challenges regarding pregnancy. Currently, there are emerging data of the effect of COVID-19 on ACHD patients, but many aspects, especially risk stratification and treatment considerations, remain unclear. In this article, we aim to discuss the broad impact of COVID-19 on ACHD patients, focusing specifically on pathophysiology, risk stratification for work, self-isolation, hospitalization, impact on pregnancy, psychosocial health, and longer-term implications for the provision of ACHD care.

3 June 2019 in Open Heart
Verified
Journal Article
Open access
PDF file
HYHayang Yang
Hayang Yang
GVGruschen R Veldtman
Gruschen R Veldtman
BBBerto J Bouma
Berto J Bouma
WBWerner Budts
Werner Budts
KNKoichiro Niwa
Koichiro Niwa
JAJamil Aboulhosn
Jamil Aboulhosn
Background: In Fontan patients with atrial arrhythmias (AA), non-vitamin K antagonist oral anticoagulants(NOACs) have a class III recommendation according to the Pediatric & Congenital Electrophysiology Society (PACES)/Heart Rhythm Society (HRS) guideline in 2014, due to lack of data on outcomes as opposed to evidence of harm. To address this gap in data, we investigated the safety and efficacy of NOACs in adults with a Fontan circulation in a worldwide study. Methods: This is an international multicentre prospective cohort study, using data from the NOTE ( n on-vitamin K antagonist o ral anticoagulants for t hrombo e mbolic prevention in patients with congenital heart disease) registry. The study population comprised consecutive adults with a Fontan circulation using NOACs. Follow-up took place at 6 months and yearly thereafter. The primary endpoints were thromboembolism and major bleeding. Secondary endpoint was minor bleeding. Results: From April 2014 onward, 74 patients (mean age 32±10 years (range 18–68), 54% male) with a Fontan circulation using NOACs were included. During a median follow-up of 1.2 (IQR 0.8–2.0) years, three thromboembolic events (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) and three major bleedings (2.9 per 100 patient-years (95% CI 0.7 to 7.6)) occurred in five atriopulmonary Fontan and one total cavopulmonary connection Fontan patients with AA. Fifteen patients experienced minor bleeding episodes (15.8 per 100 patient-years (95% CI 9.1 to 25.2)). In patients (n=37) using vitamin K antagonists (VKAs) prior to the initiation of NOAC, annual incidence of historical thromboembolic events and major bleeding were 2.4% (95% CI 0.4% to 7.4%) (n = 2) and 1.2% (95% CI 0.7% to 5.1%) (n = 1), respectively. Conclusions: In this review of the largest Fontan cohort using NOACs with prospective follow-up, NOACs appear to be well tolerated and their efficacy and safety during short-term follow-up seem comparable to VKAs. Longer term data are required to confirm these promising short-term results.

8 March 2021 in Heart
Verified
Journal Article
Open access
PDF file
MSMarkus Schwerzmann
Markus Schwerzmann
FRFrancisco Javier Ruperti-Repilado
Francisco Javier Ruperti-Repilado
HBHelmut Baumgartner
Helmut Baumgartner
BBBerto Bouma
Berto Bouma
JBJudith Bouchardy
Judith Bouchardy
MGMatthias Greutmann
Matthias Greutmann
Aims: Patients with adult congenital heart disease (ACHD) are a potentially vulnerable patient cohort in case of COVID-19. Some cardiac defects may be associated with a poor COVID-19 outcome. Risk estimation in ACHD is currently based on expert opinion. The aim of this study was to collect clinical outcome data and to identify risk factors for a complicated course of COVID-19 in patients with ACHD.Methods: Twenty-five ACHD centres in nine European countries participated in the study. Consecutive patients with ACHD diagnosed with COVID-19 presenting to one of the participating centres between 27 March and 6 June 2020 were included. A complicated disease course was defined as hospitalisation for COVID-19 requiring non-invasive or invasive ventilation and/or inotropic support, or a fatal outcome.Results: Of 105 patients with a mean age of 38±13 years (58% women), 13 had a complicated disease course, of whom 5 died. In univariable analysis, age (OR 1.3, 95% CI 1.1 to 1.7, per 5 years), ≥2 comorbidities (OR 7.1, 95% CI 2.1 to 24.5), body mass index of >25 kg/m2 (OR 7.2, 95% CI 1.9 to 28.3) and cyanotic heart disease (OR 13.2, 95% CI 2.5 to 68.4) were associated with a complicated disease course. In a multivariable logistic regression model, cyanotic heart disease was the most important predictor (OR 60.0, 95% CI 7.6 to 474.0).Conclusions: Among patients with ACHD, general risk factors (age, obesity and multiple comorbidities) are associated with an increased risk of complicated COVID-19 course. Congenital cardiac defects at particularly high risk were cyanotic lesions, including unrepaired cyanotic defects or Eisenmenger syndrome.